China SXT Pharmaceuticals, Inc. (SXTC) Earnings History
Annual and quarterly earnings data from 2016 to 2025
Loading earnings history...
SXTC EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
SXTC Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 21.1% | -154.0% | -189.8% |
| 2024 | 28.7% | -130.4% | -160.7% |
| 2023 | 21.6% | -284.4% | -301.0% |
| 2022 | 48.1% | -199.4% | -220.4% |
| 2021 | 59.4% | -46.0% | -57.5% |
Download Data
Export SXTC earnings history in CSV or JSON format
Free sign-in required to download data
China SXT Pharmaceuticals, Inc. (SXTC) Earnings Overview
As of May 8, 2026, China SXT Pharmaceuticals, Inc. (SXTC) reported trailing twelve-month net income of -$3M, reflecting -129.1% year-over-year growth. The company earned $-1.35 per diluted share over the past four quarters, with a net profit margin of -189.8%.
Looking at the long-term picture, SXTC's historical earnings data spans multiple years. The company achieved its highest annual net income of $2M in fiscal 2019.
China SXT Pharmaceuticals, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including SBFM (-$6M net income, -14.7% margin), CHNR (-$14M net income), TCMD ($20M net income, 5.8% margin), SXTC has room to improve margins relative to the peer group. Compare SXTC vs SBFM →
SXTC Earnings vs Peers
Earnings metrics vs comparable public companies
SXTC Historical Earnings Data (2016–2025)
10 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$3M | -6.6% | -$3M | $-8.18 | -189.8% | -154.0% |
| 2024 | -$3M | +47.8% | -$3M | $-3.57 | -160.7% | -130.4% |
| 2023 | -$6M | -3.5% | -$6M | $-22.23 | -301.0% | -284.4% |
| 2022 | -$6M | -108.7% | -$5M | $-137.92 | -220.4% | -199.4% |
| 2021 | -$3M | +73.3% | -$2M | $-95.48 | -57.5% | -46.0% |
| 2020 | -$10M | -768.4% | $4M | $-832.08 | -199.3% | 83.0% |
| 2019 | $2M | +29.6% | $2M | $149.67 | 22.0% | 25.2% |
| 2018 | $1M | +0.2% | $2M | $0.00 | 16.9% | 23.3% |
| 2017 | $1M | +737.3% | $2M | $0.00 | 24.3% | 32.8% |
| 2016 | $141,544 | - | $209,140 | $0.00 | 3.8% | 5.6% |
See SXTC's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SXTC Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SXTC vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonSXTC — Frequently Asked Questions
Quick answers to the most common questions about buying SXTC stock.
Is SXTC growing earnings?
SXTC EPS fell to $-1.35, with earnings declining -129.1%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-3M.
What are SXTC's profit margins?
China SXT Pharmaceuticals, Inc. net margin is -189.8%, with operating margin at -154.0%. Below-average margins reflect competitive or cost pressures.
How consistent are SXTC's earnings?
SXTC earnings data spans 2016-2025. The declining earnings trend is -129.1% YoY. Historical data enables comparison across business cycles.